FOR IMMEDIATE RELEASE
Wednesday, Nov. 10, 20045:00 p.m. Eastern Time
In an initial clinical trial led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, doctors found that up to 75 percent of people with Crohn’s disease responded to an experimental new treatment, and up to 50 percent had long-term remission of symptoms. They report these findings in the Nov. 11 issue of The New England Journal of Medicine.
Crohn’s, which affects an estimated 500,000 Americans, is an autoimmune disease that attacks the bowels, causing abdominal pain, cramping, diarrhea and rectal bleeding. In severe cases, damaged bowel sections must be surgically removed. The new treatment is an antibody designed to disable interleukin-12 (IL-12), an immune system protein involved in inflammation. People with Crohn’s produce excess IL-12. Previous studies by NIAID researcher Warren Strober, M.D., linked IL-12 to the cascade of immune system events that leads to the debilitating symptoms of Crohn’s disease.
“NIAID researchers have taken advantage of a potential target for preventing, early in the disease process, the devastating inflammation that excess IL-12 seems to trigger. Existing treatments, which often fail, attempt to interrupt inflammation far later in the process,” says Anthony S. Fauci, M.D., director of NIAID. “This is the first test of this potential new treatment in people with Crohn's disease, and we are encouraged by the results.”
The clinical trial was conducted at 15 centers in the United States, Germany and the Netherlands. Peter Mannon, M.D., and Ivan Fuss, M.D., of NIAID led the study, which enrolled 79 men and women with Crohn’s disease. Most study volunteers were randomly assigned to groups where they were injected with either low- or high-dose antibody treatments on one of two possible dosing schedules. The remaining sixteen volunteers received placebo injections.
The treatment consisted of a human antibody genetically modified to attach to and disable IL-12. High IL-12 levels in people with Crohn’s disease activate T cells, which in turn produce a variety of proteins—interferon, tumor necrosis factor, IL-6 and IL-18—that cause damage in Crohn’s disease.
After seven injections given weekly, 12 of 16 people receiving the higher dose of anti-IL-12 antibody responded to the treatment. At the end of the 24-week trial, six of those volunteers’ symptoms were in remission.
Other volunteers received seven injections, with four weeks between the first and second injection, followed by six weekly injections. In this group, 9 of 16 people receiving the higher dose had responded to the treatment at week nine. At the end of the 18-week follow-up phase, half of this group (8 people) had remission of their symptoms.
The researchers also measured levels of the other immune system proteins—interferon, tumor necrosis factor, IL-10, IL-6 and IL-18—that are produced by the activated T cells in eight volunteers who received treatment at the National Institutes of Health Clinical Center. The researchers measured the proteins before and after treatment and found that many of the inflammatory proteins had dropped dramatically by the end of treatment. The decline in these proteins suggests that blocking IL-12 worked as the doctors hoped it would, by slowing or halting the Crohn’s disease process.
“Data from this early study show us that the treatment was safe and also provide evidence that the antibody treatment may be effective against inflammation in Crohn’s disease. The next step is to test the treatment in a larger group of volunteers and seek the most effective dose and treatment schedule,” says Dr. Mannon.
Abbott Laboratories produced the anti-IL-12 antibody. Another pharmaceutical company, Wyeth, and the National Cancer Institute, also part of NIH, contributed to study costs.
Questions about forthcoming clinical trials on anti-IL-12 antibody treatment or other inflammatory bowel disease studies may be directed to the NIH Patient Recruitment and Referral Office at telephone: 1-800-411-1222 (Toll Free) or 1-301-402-6481. Also, to identify an experimental treatment study in which you may enroll, go to www.clinicaltrials.gov.
For more information on treatment of Crohn’s disease, contact: National Digestive Diseases Information Clearinghouse2 Information WayBethesda, Maryland 20892-3570United States of America
Telephone: 1-301-654-3810 or 1-800-891-5389 Fax: 1-301-907-8906 E-mail: NDDIC@info.niddk.nih.gov Web Contact Form: http://digestive.niddk.nih.gov/about/contact.htm
Further information on current treatments or clinical trials for Crohn’s disease or inflammatory bowel disease may also be found at the National Institute of Diabetes and Digestive and Kidney Diseases Web site—http://www.niddk.nih.gov
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of
infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News
releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research,
and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health ®
back to top
Last Updated November 10, 2004